Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes.
製藥公司贊助的藥物優惠券使用與2型糖尿病患者的換藥行為。
J Manag Care Spec Pharm 2024-08-30
Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
評估2型糖尿病合併心血管疾病患者使用 SGLT2 抑制劑或 GLP-1 RA 時的自費成本和治療強化。
JAMA Netw Open 2024-01-06
研究發現,對於患有2型糖尿病和心血管疾病的病患來說,高自付費用會降低他們開始使用特定糖尿病藥物的意願。研究指出,自付費用較高的病患開始使用GLP-1 RA 的可能性降低了13%,開始使用SGLT2 抑制劑的可能性降低了20%。
PubMedDOI
Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom.
英國的一項比較性同期研究:鈉葡萄糖共同轉運蛋白-2抑製劑的停用後預測因子。
Diabetes Obes Metab 2023-11-15
Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.
2019-2023年間用於2型糖尿病的葡萄糖樣肽1受體激動劑和鈉葡萄糖協同轉運蛋白2抑製劑的醫療保險處方限制。
J Manag Care Spec Pharm 2024-02-07
Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.
糖尿病患者第二線治療中磺胺脲類藥物與新型糖尿病藥物的效果和成本效益比較。
BMJ Open Diabetes Res Care 2024-05-27
Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care.
2型糖尿病患者在常規護理中對新型降糖藥物的依從性和持續性。
Diabetes Res Clin Pract 2024-06-14
Trends in antidiabetes medication use among hospitalised patients with type 2 diabetes: a retrospective single-centre cohort study.
住院病人中2型糖尿病抗糖尿病藥物使用趨勢:一項回顧性單中心世代研究。
BMJ Open 2024-07-01
Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study.
保險對新型糖尿病藥物使用的差異:一項全國代表性隊列研究。
J Gen Intern Med 2024-07-31
A Real-world Study Evaluating the Clinical Factors Associated with the Initial SGLT2 Inhibitor Prescription.
評估與初始 SGLT2 抑制劑處方相關的臨床因素的實際研究。
J Health Care Poor Underserved 2024-08-12